Articles > Popular publications > PR Newswire press releases > January-March 2008 > Thursday, February 28

Article: Evotec Starts Phase II in Smoking Cessation with EVT 302.

Article from:
PR Newswire
Article date:
February 28, 2008
Copyright

HAMBURG, Germany and OXFORD, England, February 28 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) today announced the start of its first Phase II study for EVT 302 in smoking cessation, a reversible and highly selective inhibitor of monoamine oxidase B (MAO-B).

This double-blind, three-way cross-over study is designed to investigate the influence of EVT 302 on craving and withdrawal symptoms after short-term deprivation of cigarettes in 90 smokers. Smokers will receive a single dose of EVT 302, nicotine, and placebo in a random order. The effect of EVT 302 on craving when combined with nicotine replacement therapy will be assessed as a ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: Evotec Discontinues EVT 301 Development Programme.

  
  PR Newswire; 
  September 13, 2006 ;  
  
  
 
  700+ words
... ... programmes in clinical development: EVT 201, a partial positive allosteric ... treatment of insomnia, and EVT 101, a subtype selective NMDA ... com/ Contact: Evotec AG Anne Hennecke Director, Investor Relations ... 40-56081-333 E-Mail: anne.hennecke@evotec.com CONTACT: Contact ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec Announces Initiation of Phase I Clinic Trial With ...

  
  PR Newswire; 
  November 14, 2005 ;  
  
  
 
  700+ words
... ... Notes to Editors: About EVT 101 EVT 101 is being developed for the ... Phase I clinical programmes: EVT 201, a GABAA modulator for the treatment of insomnia, and EVT 101, a subtype selective NMDA ... com/ Contact: Evotec AG Anne Hennecke Director, Investor Relations ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec Initiates Second Phase II Clinical Trial With Insomnia ...

  
  PR Newswire; 
  November 17, 2006 ;  
  
  
 
  652 words
... ... this second patient trial with EVT 201 is to assess "total sleep ... Phase II clinical trial with EVT 201 which is ongoing. Prior ... in healthy male volunteers, EVT 201 significantly reduced ... events. Contact: Evotec AG Anne Hennecke Director, Investor Relations ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec to Present Details of the Positive Phase II Study in ...

  
  PR Newswire; 
  August 28, 2007 ;  
  
  
 
  700+ words
... ... the first Phase II study with EVT 201 were very positive in terms ... subjects with induced insomnia, EVT 201 significantly reduced Wake ... development and on the market. EVT 201 showed no tolerance/dependence ... joern.aldag@evotec.com Anne Hennecke Senior Vice President Investor ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec Successfully Completes Single Ascending Dose Component of ...

  
  PR Newswire; 
  February 3, 2006 ;  
  
  
 
  700+ words
... ... results of the complete Phase I trials for EVT 101 in Q3 2006. Notes to Editors About EVT 101 EVT 101 is being developed for the treatment ... efficacy of the drug. Contact: Evotec AG Anne Hennecke Director, Investor Relations & Corporate ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec Initiates Phase II Clinical Trial With EVT 201 for ...

  
  PR Newswire; 
  September 21, 2006 ;  
  
  
 
  700 words
... ... in healthy male volunteers, EVT 201 significantly reduced ... results of our previous studies of EVT 201 in a traffic noise model ... this first patient trial with EVT 201 are to assess "wake after ... quantity. Contact: Evotec AG Anne Hennecke Director, Investor Relations ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec Announces Positive Phase I/II Clinical Trial Results With ...

  
  PR Newswire; 
  June 8, 2006 ;  
  
  
 
  700+ words
... ... The results indicate that EVT 201 is a substance that could ... dose-response relationship of EVT 201 allowing us to select the ... 5, 2.0 and 2.5 mg) of EVT 201 compared to placebo in 12 ... development. Contact: Evotec AG Anne Hennecke Director, Investor Relations ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Evotec Initiates its First Phase I Clinical Study With EVT ...

  
  PR Newswire; 
  March 22, 2007 ;  
  
  
 
  640 words
... ... therapeutic dose range of EVT 302 for the upcoming safety and efficacy studies. EVT 302 is an orally active ... compound was in-licensed, EVT 302 was safe and well tolerated ... physicians. Contact: Evotec AG Anne Hennecke SVP, Investor Relations ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives